Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

2012492 citationsJournal Articlebronze Open Access

Authors

S. Gourgou-Bourgade · Centre Oscar Lambret

Caroline Mollévi · Centre Oscar Lambret

Françoise Desseigne · Centre Oscar Lambret

Marc Ychou · Centre Oscar Lambret

Olivier Bouché · Délégation Centre-Est

Rosine Guimbaud · Centre Oscar Lambret

Y. Bécouarn ·

Abstract

FOLFIRINOX significantly reduces QoL impairment compared with gemcitabine in patients with metastatic pancreatic cancer. Furthermore, baseline QoL scores improved estimation of survival probability when added to baseline clinical and demographic variables.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Colorectal Cancer Treatments and Studies Neuroendocrine Tumor Research Advances

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 1, pp. 23-29

DOI: 10.1200/jco.2012.44.4869

Field-Weighted Citation Impact: 16.33

Command Palette

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Authors

Abstract

Topics & Keywords

Publication Details